Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.

Kovatchev BP, Crean J, McCall A

Diabetes technology & therapeutics1 Oct 2008Cited by 9 (Europe PMC)

PMID18715216PMCIDPMC2979337DOI10.1089/dia.2007.0295PepBankPUB-18715216

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In patients with type 1 diabetes, pramlintide reduced the pre- to postprandial glucose rate of change versus placebo.
In plain wordsIn patients with type 1 diabetes, pramlintide reduced meal-related glucose changes more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePre- to postprandial glucose rate of change
Study
n = 248
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30/60 microg at each meal · subcutaneousAs given in this study (human).
Source sentences
Summary
Compared with placebo, pramlintide significantly attenuated the pre- to postprandial BG rate of change (F=83.8, P<0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Self-monitored BG (SMBG) records were retrospectively analyzed from a randomized, double-blind, placebo-controlled study of the effects of pramlintide on intensively treated patients with type 1 diabetes.
Summary · context
Two groups--pramlintide (n=119), 30/60 microg administered subcutaneously at each meal, or placebo (n=129)--were matched by age, gender, and baseline hemoglobin A1C.
Report a problemFND-1871521601
02HumanObservational studyEfficacy outcome
In patients with type 1 diabetes, average post-meal glucose was lower with pramlintide than placebo.
In plain wordsIn patients with type 1 diabetes, glucose after meals was lower with pramlintide than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseAverage post-meal glucose
Study
n = 248
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30/60 microg at each meal · subcutaneousAs given in this study (human).
Measurements
Post-meal glucose
8.4 mmol/L
pramlintide
Post-meal glucose
9.7 mmol/L
placebo
Source sentences
Summary
Consequently, in pramlintide-treated patients, the average post-meal BG (8.4 vs. 9.7 mmol/L [151.2 vs. 174.6 mg/dL]) and postprandial HBGI were significantly lower than placebo (both P<0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Self-monitored BG (SMBG) records were retrospectively analyzed from a randomized, double-blind, placebo-controlled study of the effects of pramlintide on intensively treated patients with type 1 diabetes.
Summary · context
Two groups--pramlintide (n=119), 30/60 microg administered subcutaneously at each meal, or placebo (n=129)--were matched by age, gender, and baseline hemoglobin A1C.
Report a problemFND-1871521602
03HumanObservational studyEfficacy outcome
In patients with type 1 diabetes, pramlintide reduced postprandial HBGI versus placebo.
In plain wordsIn patients with type 1 diabetes, the high-glucose risk index after meals was lower with pramlintide than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial high blood glucose index
Study
n = 248
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30/60 microg at each meal · subcutaneousAs given in this study (human).
Source sentences
Summary
Consequently, in pramlintide-treated patients, the average post-meal BG (8.4 vs. 9.7 mmol/L [151.2 vs. 174.6 mg/dL]) and postprandial HBGI were significantly lower than placebo (both P<0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Self-monitored BG (SMBG) records were retrospectively analyzed from a randomized, double-blind, placebo-controlled study of the effects of pramlintide on intensively treated patients with type 1 diabetes.
Summary · context
Two groups--pramlintide (n=119), 30/60 microg administered subcutaneously at each meal, or placebo (n=129)--were matched by age, gender, and baseline hemoglobin A1C.
Report a problemFND-1871521603
04HumanObservational studySafety outcome
In patients with type 1 diabetes, pramlintide was not associated with increased preprandial hypoglycemia risk, measured by LBGI.
In plain wordsIn patients with type 1 diabetes, pramlintide did not increase low-glucose risk before meals compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changePreprandial hypoglycemia risk
Study
n = 248
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
30/60 microg at each meal · subcutaneousAs given in this study (human).
Source sentences
Summary
The reduction in postprandial hyperglycemia in pramlintide-treated patients occurred without increased risk for preprandial hypoglycemia as quantified by the LBGI.
2 context sentences(design, population, supporting numbers)
Summary · context
Self-monitored BG (SMBG) records were retrospectively analyzed from a randomized, double-blind, placebo-controlled study of the effects of pramlintide on intensively treated patients with type 1 diabetes.
Summary · context
Two groups--pramlintide (n=119), 30/60 microg administered subcutaneously at each meal, or placebo (n=129)--were matched by age, gender, and baseline hemoglobin A1C.
Report a problemFND-1871521605
05HumanObservational studyEfficacy outcome
In pramlintide-treated patients with type 1 diabetes, post-meal glucose did not vary significantly throughout the day.
In plain wordsIn pramlintide-treated patients with type 1 diabetes, glucose after meals did not vary significantly across the day.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeDaily variation in post-meal glucose
Study
n = 119
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30/60 microg at each meal · subcutaneousAs given in this study (human).
Source sentences
Summary
post-meal BG did not vary significantly throughout the day in pramlintide-treated patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Self-monitored BG (SMBG) records were retrospectively analyzed from a randomized, double-blind, placebo-controlled study of the effects of pramlintide on intensively treated patients with type 1 diabetes.
Summary · context
Two groups--pramlintide (n=119), 30/60 microg administered subcutaneously at each meal, or placebo (n=129)--were matched by age, gender, and baseline hemoglobin A1C.
Report a problemFND-1871521604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00107107

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

AstraZenecan = 190Nov 2002 to Jun 2005

Diabetes Mellitus, Type 1

Trial page ClinicalTrials.govUpdated 23 Sept 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.